突发公共卫生事件下疫苗效力试验的设计。
Design of vaccine efficacy trials during public health emergencies.
机构信息
Department of Biostatistics, University of Florida, Gainesville, FL, USA.
World Health Organization, Geneva, Switzerland.
出版信息
Sci Transl Med. 2019 Jul 3;11(499). doi: 10.1126/scitranslmed.aat0360.
Abstract
Public health emergencies, such as an Ebola disease outbreak, provide a complex and challenging environment for the evaluation of candidate vaccines. Here, we outline the need for flexible and responsive vaccine trial designs to be used in public health emergencies, and we summarize recommendations for their use in this setting.
摘要
公共卫生突发事件，如埃博拉疫情爆发，为候选疫苗的评估提供了一个复杂而具有挑战性的环境。在这里，我们概述了在公共卫生突发事件中灵活和响应性疫苗试验设计的必要性，并总结了在这种情况下使用这些设计的建议。
相似文献
1
Design of vaccine efficacy trials during public health emergencies.突发公共卫生事件下疫苗效力试验的设计。
Sci Transl Med. 2019 Jul 3;11(499). doi: 10.1126/scitranslmed.aat0360.
2
Arranging good clinical practices training and trial monitoring for a vaccine efficacy study during a public health emergency of international concern.在国际关注的突发公共卫生事件期间，为一项疫苗效力研究安排良好临床实践培训和试验监测。
Vaccine. 2020 May 19;38(24):4050-4056. doi: 10.1016/j.vaccine.2020.03.015. Epub 2020 Apr 11.
3
Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.在公共卫生突发事件中，严格的临床试验设计至关重要。
Clin Infect Dis. 2018 Apr 17;66(9):1467-1469. doi: 10.1093/cid/cix1032.
4
Improving vaccine trials in infectious disease emergencies.改善传染病紧急情况下的疫苗试验。
Science. 2017 Jul 14;357(6347):153-156. doi: 10.1126/science.aam8334.
5
Regulating clinical trials in a resource-limited setting during the Ebola public health emergency in Sierra Leone.在塞拉利昂埃博拉公共卫生紧急情况下，对资源有限环境下的临床试验进行监管。
Trials. 2022 Jun 6;23(1):466. doi: 10.1186/s13063-022-06416-4.
6
Regulatory policy for research and development of vaccines for public health emergencies.突发公共卫生事件疫苗研发的监管政策
Expert Rev Vaccines. 2016 Sep;15(9):1075-7. doi: 10.1080/14760584.2016.1188695. Epub 2016 May 27.
7
Vaccines in a hurry.仓促推出的疫苗。
Vaccine. 2009 May 26;27(25-26):3295-8. doi: 10.1016/j.vaccine.2009.02.030. Epub 2009 Feb 20.
8
Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic.突发公共卫生事件期间研究的伦理审查——世界卫生组织伦理审查委员会在埃博拉病毒病疫情期间的经验
BMC Med Ethics. 2017 Jun 26;18(1):43. doi: 10.1186/s12910-017-0201-1.
9
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.赋予 COVID-19 候选疫苗紧急使用授权：对 COVID-19 疫苗试验的影响。
Lancet Infect Dis. 2021 Apr;21(4):e103-e109. doi: 10.1016/S1473-3099(20)30923-3. Epub 2020 Dec 8.
10
Considerations for use of Ebola vaccine during an emergency response.在紧急响应期间使用埃博拉疫苗的注意事项。
Vaccine. 2019 Nov 15;37(48):7190-7200. doi: 10.1016/j.vaccine.2017.08.058. Epub 2017 Sep 7.
引用本文的文献
1
Adopting the estimand framework in prophylactic vaccine trials.在预防性疫苗试验中采用估计量框架。
Vaccine. 2025 Sep 3;64:127645. doi: 10.1016/j.vaccine.2025.127645.
2
Estimation of Lassa fever incidence rates in West Africa: Development of a modeling framework to inform vaccine trial design.西非拉沙热发病率的估计：用于指导疫苗试验设计的建模框架的开发。
PLoS Negl Trop Dis. 2025 Jul 29;19(7):e0012751. doi: 10.1371/journal.pntd.0012751. eCollection 2025 Jul.
3
Designs for Vaccine Studies.疫苗研究设计。
Annu Rev Stat Appl. 2025 Mar;12:1-18. doi: 10.1146/annurev-statistics-033121-120121. Epub 2024 Oct 30.
4
Acceptance and affordability of malaria vaccines: issues relating to hesitancy and willingness to pay amongst Nigerian parents of under-five children.疟疾疫苗的可接受性和可负担性：与尼日利亚五岁以下儿童家长的犹豫态度和支付意愿相关的问题。
Malar J. 2025 Feb 7;24(1):36. doi: 10.1186/s12936-025-05268-y.
5
Two centuries of vaccination: historical and conceptual approach and future perspectives.两百年来的疫苗接种：历史与概念方法及未来展望。
Front Public Health. 2024 Jan 9;11:1326154. doi: 10.3389/fpubh.2023.1326154. eCollection 2023.
6
A review on Zika vaccine development.寨卡病毒疫苗的开发研究综述。
Pathog Dis. 2024 Feb 7;82. doi: 10.1093/femspd/ftad036.
7
Public Health Impacts of Vaccines for COVID-19 and Beyond: Opportunities to Overcome Technical and Regulatory Barriers for Randomized Trials.新冠疫苗和其他疫苗的公共卫生影响：克服随机试验技术和监管障碍的机会。
Am J Public Health. 2023 Jul;113(7):778-785. doi: 10.2105/AJPH.2023.307302. Epub 2023 Apr 27.
8
Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2.回顾性观察研究估计疫苗对 SARS-CoV-2 二次攻击率的影响。
Am J Epidemiol. 2023 Jun 2;192(6):1016-1028. doi: 10.1093/aje/kwad046.
9
Diversity's Pandemic Distractions.多样性在疫情期间的干扰因素。
Health Matrix Clevel. 2022;32(1):149-213.
10
COVID-19 site readiness initiative: Building clinical trial capacity for vaccine efficacy trials in Latin America in response to the pandemic.COVID-19现场准备计划：为应对大流行在拉丁美洲建立疫苗疗效试验的临床试验能力。
Vaccine X. 2022 Nov 8;12:100238. doi: 10.1016/j.jvacx.2022.100238. eCollection 2022 Dec.
本文引用的文献
1
WHO's Blueprint List of Priority Diseases.世界卫生组织重点疾病蓝图清单。
JAMA. 2018 May 15;319(19):1973. doi: 10.1001/jama.2018.5712.
2
DESIGN OF VACCINE TRIALS DURING OUTBREAKS WITH AND WITHOUT A DELAYED VACCINATION COMPARATOR.疫情期间有和没有延迟接种对照的疫苗试验设计
Ann Appl Stat. 2018 Mar;12(1):330-347. doi: 10.1214/17-AOAS1095. Epub 2018 Mar 9.
3
Simulations for designing and interpreting intervention trials in infectious diseases.用于设计和解释传染病干预试验的模拟
BMC Med. 2017 Dec 29;15(1):223. doi: 10.1186/s12916-017-0985-3.
4
Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.2016年几内亚埃博拉病毒病疫情期间扩大使用rVSV-ZEBOV进行环围式疫苗接种：一份操作及疫苗安全性报告。
Lancet Infect Dis. 2017 Dec;17(12):1276-1284. doi: 10.1016/S1473-3099(17)30541-8. Epub 2017 Oct 9.
5
WHO R&D Blueprint: a global coordination mechanism for R&D preparedness.世界卫生组织研发蓝图：研发准备的全球协调机制。
Lancet. 2017 Jun 24;389(10088):2469-2470. doi: 10.1016/S0140-6736(17)31635-5.
6
CEPI-a new global R&D organisation for epidemic preparedness and response.流行病防范创新联盟——一个新的全球流行病防范与应对研发组织。
Lancet. 2017 Jan 21;389(10066):233-235. doi: 10.1016/S0140-6736(17)30131-9. Epub 2017 Jan 19.
7
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).一种重组水疱性口炎病毒载体疫苗预防埃博拉病毒病的有效性和效果：几内亚环状疫苗接种、开放标签、整群随机试验（埃博拉到此为止！）的最终结果
Lancet. 2017 Feb 4;389(10068):505-518. doi: 10.1016/S0140-6736(16)32621-6. Epub 2016 Dec 23.
8
Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research.解读阶梯楔形设计的假设：以埃博拉疫苗研究为例。
J Med Ethics. 2016 Dec;42(12):797-804. doi: 10.1136/medethics-2015-103292. Epub 2016 Oct 17.
9
Implementing an Ebola Vaccine Study - Sierra Leone.在塞拉利昂开展埃博拉疫苗研究
MMWR Suppl. 2016 Jul 8;65(3):98-106. doi: 10.15585/mmwr.su6503a14.
10
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges.评估疫苗预防埃博拉病毒病感染有效性的模拟引导3期试验设计：统计学考量、设计原理及挑战
Clin Trials. 2016 Feb;13(1):57-65. doi: 10.1177/1740774515621059. Epub 2016 Jan 14.
Zotero 插件